1-3 of 3
David Readett
Close
Sort by
Journal Articles

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis

Clinical Trials & Observations
Carlton D. Dampier, Marilyn Jo Telen, Ted Wun, R. Clark Brown, Payal Desai, Fuad El Rassi, Beng Fuh, Julie Kanter, Yves Pastore, Jennifer Rothman, James G. Taylor, VI, David Readett, Krupa M. Sivamurthy, Brinda Tammara, Li-Jung Tseng, Jay Nelson Lozier, Helen Thackray, John L. Magnani, Kathryn L. Hassell
Journal: Blood
Blood (2023) 141 (2): 168–179.
https://doi.org/10.1182/blood.2022015797
Published: 2023
Includes: Supplemental data
Journal Articles

Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

Carlton D. Dampier, MD, Marilyn J. Telen, MD, Ted Wun, MD, Wally R Smith, MD, R. Clark Brown, MD PhD, Payal Desai, MD, Fuad A El Rassi, MD, Julie Kanter, MD, Beng R. Fuh, MD, Yves D. Pastore, MD, Jennifer A. Rothman, MD, James G. Taylor, MD, David Readett, BM, BS, MRCP, Jay N Lozier, MDPhD, John L. Magnani, PhD, Helen M Thackray, MD, Kathryn L. Hassell, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-134803
Published: 2020
Journal Articles

Effect of Renal Impairment on the Pharmacokinetics and Safety of Rivipansel in Subjects with Renal Impairment and in Healthy Subjects

Brinda Tammara, PhD, Kelly Ryan, Anna Plotka, Frank E. Shafer, MD, Hua Wei, David Readett, Annie Fang, Joan Korth-Bradley, PharmD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1083.
https://doi.org/10.1182/blood-2018-99-111926
Published: 2018